From Plant to Patient.
AUTHENTICATED IBOGA AND THE STANDARDS THE CATEGORY RUNS ON.
GMP-GRADE IBOGAINE FOR CLINICAL TRIAL SUPPORT.
IBOGAINE DOESN'T SCALE WITHOUT INFRASTRUCTURE.
WE'RE BUILDING IT.
VISION
The Medicine is Coming.
The Supply Chain isn't Ready.
A dozen US states are funding ibogaine research. Federal interest has reached Senate testimony. Clinical programs are advancing on both coasts. But the material itself still moves through informal channels with no verified identity, no documented origin, and no consistent potency - a 2020 analysis found more than eighteen-fold variation in ibogaine content across products sold as iboga root bark globally.
Pharmagaine exists to close that gap. Authenticated species, documented origin, third-party testing, and a chain of custody from plant to patient - so that when the medicine arrives, the supply is already qualified.
Two forms. One standard. We have built a company that supplies cGMP ibogaine HCl (IBO-9000), full-spectrum total alkaloid iboga (Ibogenyx Spectrum), and root bark full-spectrum capsules (Ibogenyx) - because the category needs these three formats, and neither is a substitute for the other in the treatment of patients at different points in the therapy model.
PROVENANCE
The Future of Ibogaine Doesn't Start in a Lab. It Starts at the Source.
Iboga has been used in Central Africa for centuries. What it has never had is a documented pathway from the forest to the clinic. We are building one - and the science that qualifies it.
Legal Documented Pathway
Government-licensed export. Every plant tagged, measured, and recorded.
Nagoya-Aligned Benefit Sharing
Access and benefit-sharing agreements signed with the communities who have kept this tree.
Genomics and Analytical Science
Reference genome underway with leading institutions in the US and Europe, with third-party alkaloid chemistry on every batch.
Rooted in Central Africa
Field operations, agronomy, and staff where the plant grows.
Clinic-Ready Products
Finished dosage forms with batch COAs and QR-linked verification, built for professional use.
OUR ADVANTAGE
World's Largest Licensed Cultivated Iboga Plantation.
LICENSED. AUTHENTICATED. DOCUMENTED.
125
Acres of Farming Land Adjacent to Wild Documented Population
5,000
Mature Iboga Plants Ready for Full Plant Extraction
Pharmagaine holds a fifty-hectare licensed concession in Équateur Province, in the heart of the plant's native range — where Tabernanthe iboga has grown wild for millennia, and where wild populations nearby give us the genetic baseline the cultivated stock is built on.
Growing iboga under license, on documented land, changes what the category can promise. Material from informal channels arrives with no verified identity and no record of where it came from. Ours arrives tagged to the plant, tested by third-party labs, and traceable from the forest to the clinic — the difference between a shipment and a batch.
Operating under government-issued cultivation and export authorisation from the DRC, Pharmagaine replaces unlicensed wild harvesting with a legal, documented supply for clinicians and researchers worldwide - with benefit-sharing agreements signed with the communities who have kept this tree for generations.
CENTER OF EXCELLENCE SCHEDULED FOR 2027 IN KINSHASA
cGMP
cGMP Production Facility
ISO 9001
Quality Management Systems
Our Center of Excellence in Kinshasa will be built to the highest international standards so that we can ensure that our research partners, pharmaceutical and therapeutic clients have the most reliable and purest source of Ibogaine and other Iboga-derived Alkaloids possible.
RESEARCH PARTNERSHIPS FOCUSED ON IP & DRUG DEVELOPMENT PARTNERSHIPS
8
Research Partners Active & Developing Solutions
$37.7B
Global Drug Addiction Treatment Market (2027)
Pharmagaine supports research across three fronts.
Plant Science: Reference genome assembly, chemotype mapping, and alkaloid characterization with leading institutions in the US and Europe.
Preclinical: Comparative studies of full-spectrum iboga against isolated ibogaine, run independently by academic partners.
Clinical: Supplying qualified material to investigator-led programs advancing toward controlled trials in opioid use disorder and PTSD (including Phase 2b Trial).
The science is early.
The supply it depends on shouldn't be.
WHY PHARMAGAINE
Built to pharmaceutical standards, from the first plant.
We believe the next generation of medicine has to be both rigorous and responsible - and that in this category, the two are the same problem. Material you cannot trace is material you cannot dose.
Pharmagaine combines regulatory and pharmaceutical discipline with agronomy, genomics, and long-standing relationships in the DRC. We work to pharmaceutical standards in the lab and to community standards in the field, and we don't treat either as optional.
The industry has never answered the simplest question in the category: where does the material come from, and can you prove it?
That is the question we exist to answer.
OUR PRODUCTS
Three Product Grades.
One Verified Chain of Custody.
Authenticated Tabernanthe iboga root bark in clinic-ready capsules. Batch-tested, QR-verified, and traceable to the plant it came from.
Purified total alkaloid extract retaining the full iboga profile. Standardized potency, third-party assayed, formulated for research and clinical partners.
Pharmaceutical-grade ibogaine HCl produced to cGMP standards. European-ready and In development with a US contract manufacturer.
PHARMAGAINE OPPORTUNITY
US Opioid Crisis
$1.3T
Annual Cost of Opioid Crisis to US Economy
332M
Number of People Globally Suffering from Depression
$37.7B
Size of the Global Drug Addiction Treatment Market
18X
Variation Fold in Iboga Products Sold Globally
COLLABORATION
Industry Groups We've Supported
